Eli Lilly's newly launched weight-loss pill, Foundayo, has begun to make its mark in the U.S. obesity treatment market, recording 1,390 prescriptions in its first week. This follows the approval of the drug on April 1 and its subsequent availability through retail pharmacies starting April 9. In comparison, Novo Nordisk's Wegovy oral tablets achieved 3,071 prescriptions within just four days of their launch on January 5. Analysts, including Trung Huynh from RBC Capital Markets, caution that early prescription data may not fully represent the market dynamics and suggest that weeks 8-12 will provide a clearer picture of Foundayo's performance. Despite the early figures, the competition between Eli Lilly and Novo Nordisk is intensifying, as both companies aim to capture a larger share of the obesity market, which has traditionally been dominated by injectable treatments. Following the launch, Eli Lilly's shares saw a 1.6% increase in premarket trading, indicating investor optimism about Foundayo's potential.